death
worldwid
coronaviru
diseas
covid
april
incumb
research
acceler
clinic
trial
readili
avail
potenti
accept
safe
therapi
could
reduc
rise
death
toll
sever
acut
respiratori
syndrom
coronaviru
gain
access
host
cell
via
angiotensinconvert
enzym
express
type
ii
surfactantsecret
alveolar
cell
lung
sever
associ
major
immun
inflammatori
respons
abund
neutrophil
lymphocyt
macrophag
immun
mediat
mediat
import
drive
immun
patholog
remain
elucid
death
chiefli
due
diffus
alveolar
damag
pulmonari
oedema
hyalin
membran
format
interstiti
mononuclear
inflammatori
infiltr
compat
earlyphas
adult
respiratori
distress
syndrom
ard
prevent
ard
death
patient
press
health
emerg
antitumour
necrosi
factor
tnf
antibodi
use
year
sever
case
autoimmun
inflammatori
diseas
rheumatoid
arthriti
inflammatori
bowel
diseas
ankylos
spondyl
ten
report
sept
us
food
drug
administr
approv
four
offlabel
indic
antitnf
therapi
indic
tnf
valid
target
mani
inflammatori
diseas
tnf
present
blood
diseas
tissu
patient
tnf
import
nearli
acut
inflammatori
reaction
act
amplifi
inflamm
propos
antitnf
therapi
evalu
patient
hospit
admiss
prevent
progress
need
intens
care
support
evid
inflammatori
excess
patient
lung
patholog
characteris
capillari
leakag
fluid
recruit
immuneinflammatori
lymphocyt
neutrophil
macrophag
impli
role
adhes
molecul
chemokin
cytokin
target
vascular
endothelium
cytokin
upregul
document
patient
upregul
proinflammatori
cytokin
blood
includ
interleukin
il
tnf
interferon
initi
report
compris
trial
sever
critic
patient
china
case
studi
franc
clinic
benefit
receptor
antibodi
tocilizumab
suggest
cytokin
import
cytokin
storm
control
clinic
trial
progress
although
mani
potenti
drug
candid
reduc
inflamm
drug
antitnf
antibodi
infliximab
adalimumab
potenti
effect
wide
avail
well
establish
safeti
profil
potenti
role
antitnf
therapi
thu
warrant
consider
preclin
studi
suggest
respons
sever
respiratori
syncyti
viru
rsv
influenza
mice
amelior
antitnf
therapi
reduc
weight
loss
diseas
durat
cell
fluid
infiltr
research
suggest
potenti
rational
use
antitnf
therapi
viral
pneumonia
especi
given
known
mechan
action
tnf
revers
tnfinduc
immunopatholog
tnf
blockad
multipl
diseas
known
tnf
produc
type
inflamm
especi
acut
phase
import
coordin
develop
inflammatori
respons
howev
much
product
tnf
long
becom
immun
suppress
blockad
tnf
alon
clinic
effect
mani
circumst
diseas
despit
presenc
mani
proinflammatori
cytokin
mediat
evid
tnf
depend
cytokin
cascad
rheumatoid
arthriti
tissu
upon
bacteri
challeng
baboon
thu
tnf
block
rapid
ie
h
decreas
concentr
patient
activ
rheumatoid
arthriti
importantli
reduct
adhes
molecul
vascular
endotheli
growth
factor
also
known
vascular
permeabl
factor
denot
import
capillari
leak
furthermor
reduct
leucocyt
traffick
occur
inflam
tissu
joint
due
reduct
adhes
molecul
chemokin
reduct
cell
content
exud
final
antitnf
infus
tissu
tnf
reduc
pass
blood
bound
antitnf
antibodi
blood
concentr
immunoreact
biolog
inact
tnf
increas
ten
time
infus
reason
possibl
singl
infus
antitnf
antibodi
might
reduc
process
occur
lung
inflamm
reduc
tnf
inflammatori
mediat
cellular
exud
would
best
time
intervent
antitnf
therapi
patient
postul
earlier
better
hospit
admiss
might
answer
patient
alreadi
initi
antivir
immun
sever
day
balanc
struck
stage
intervent
ensur
patient
suffici
risk
poor
outcom
appropri
monitor
propos
initi
assess
antitnf
therapi
clinic
trial
patient
moder
diseas
admit
hospit
requir
oxygen
support
intens
care
treatment
approach
prove
benefici
good
safeti
profil
treatment
commun
peopl
identifi
high
risk
progress
hospit
admiss
might
consid
rang
avail
formul
administr
rout
antitnf
product
could
facilit
treatment
approach
tradeoff
immun
viru
clearanc
use
power
antiinflammatori
drug
acut
viral
diseas
approach
caution
risk
increas
viral
replic
bacteri
infect
lung
viral
infect
higher
infecti
dose
greater
tissu
damag
viral
replic
ensu
immun
respons
anim
model
resembl
lung
viral
infect
human
immun
respons
viru
great
even
moder
reduct
inflamm
beneficialeg
mice
sever
pneumonia
rsv
influenza
benefit
antitnf
treatment
without
compromis
viral
clearanc
lung
architectur
preserv
howev
concern
safeti
import
consid
new
therapi
would
antitnf
therapi
increas
risk
bacteri
fungal
superinfect
respiratori
viral
infect
superinfect
organ
occur
sever
end
diseas
spectrum
mani
research
group
elucid
mechan
respons
anecdot
evid
suggest
bacteria
might
role
covid
although
remain
confirm
bacteria
gain
foothold
faster
lung
damag
experiment
studi
suggest
durat
inflamm
limit
associ
collater
lung
damag
bacteri
superinfect
reduc
concern
antitnf
therapi
might
increas
risk
bacteri
infect
yet
two
randomis
studi
critic
unwel
patient
septic
shock
show
monoclon
antitnf
therapi
good
safeti
data
evid
increas
secondari
bacteri
infect
antitnf
treat
group
observ
trial
rheumatoid
arthriti
patient
seriou
infect
risk
sepsi
death
reduc
patient
tnf
inhibitor
compar
synthet
diseasemodifi
antirheumat
drug
dmard
patient
tnf
inhibitor
develop
sepsi
seriou
infect
die
compar
patient
dmard
develop
sepsi
die
paradox
anoth
class
tnf
inhibitor
igfc
fusion
protein
etanercept
associ
moder
increas
mortal
randomis
trial
treatment
sepsi
possibl
due
faster
offrat
tnf
potenti
result
redistribut
bioavail
pathogen
tnf
rather
clearanc
interest
whether
safeti
antitnf
therapi
patient
might
glean
analysi
cours
patient
inflammatori
bowel
diseas
ibd
rheumatoid
arthriti
alreadi
antitnf
treatment
april
secureibd
coronaviru
ibd
report
databas
regist
outcom
ibd
patient
patient
antitnf
therapi
alon
recov
without
hospitalis
one
patient
die
contrast
half
patient
sulfasalazin
mesalamin
recov
without
hospit
admiss
six
patient
die
thu
ibd
patient
antitnf
therapi
fare
wors
treat
drug
insuffici
data
make
conclus
better
outcom
believ
suffici
evid
support
clinic
trial
antitnf
therapi
patient
averag
day
hospit
admiss
ard
propos
antitnf
therapi
initi
earli
practic
preliminari
evid
benefit
safeti
antitnf
therapi
hospitalis
patient
suggest
consider
given
hospit
treatment
patient
high
risk
older
peopl
preexist
condit
monitor
appropri
mf
rnm
held
patent
expir
use
infliximab
methotrex
inflammatori
arthriti
receiv
royalti
johnson
johnson
abbvi
amgen
ucb
none
respiratori
critic
care
financi
asset
kennedi
trust
rheumatolog
research
larg
deriv
patent
royalti
antitnf
antibodi
jnw
gener
partner
laterel
ventur
partner
role
unrel
topic
comment
sth
nonexecut
board
director
ned
sharehold
synairgen
synairgen
conduct
clinic
trial
inhal
ifn
patient
unrel
comment
sth
play
direct
role
synairgen
trial
role
ned
sth
direct
interest
antitnf
therapeut
refer
comment
gw
receiv
director
fee
includ
option
share
founder
director
bicycl
therapeut
plc
unrel
topic
comment
founder
cambridg
antibodi
technolog
codevelop
antitnf
antibodi
adalimumab
advis
peptech
domanti
antitnf
develop
patent
gw
truste
kennedi
trust
rheumatolog
research
financi
asset
larg
deriv
patent
royalti
antitnf
antibodi
dr
report
person
fee
consult
drug
safeti
glaxosmithklin
unrel
topic
comment
mr
th
declar
compet
interest
